The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Early disease progression in patients (pts) with newly diagnosed localized nasal extranodal NK/T-cell lymphoma, nasal type (ENKL) treated with radiotherapy with dexamethasone, etoposide, ifosfamide, and carboplatin (RT-DeVIC).
 
Motoko Yamaguchi
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; Kyowa Hakko Kirin; Nippon Shinyaku; Takeda
Consulting or Advisory Role - ERYTECH Pharma
 
Ritsuro Suzuki
Honoraria - Bristol-Myers Squibb Japan; Celgene; Chugai Pharma; Kyowa Hakko Kirin; Meiji Seika Kaisha; Merck Sharp & Dohme; Mochida Pharmaceutical Co. Ltd.; Novartis; Otsuka; Sawai Pharmaceutical Co; Shionogi; Sumitomo Dainippon; Takeda
Consulting or Advisory Role - Gilead Sciences; Jazz Pharmaceuticals; Mundipharma
 
Masahiko Oguchi
No Relationships to Disclose
 
Naoko Asano
Honoraria - Chugai Pharma; Janssen
 
Kana Miyazaki
Honoraria - Chugai Pharma; Eisai; Takeda
 
Yasuhito Terui
No Relationships to Disclose
 
Nobuko Kubota
No Relationships to Disclose
 
Takeshi Maeda
No Relationships to Disclose
 
Yukio Kobayashi
Consulting or Advisory Role - Celgene; Novartis; Pfizer
Research Funding - Amgen; Astellas Pharma; Boehringer Ingelheim; Celgene; Daiichi Sankyo; Novartis; Otsuka; Pfizer
Travel, Accommodations, Expenses - Daiichi Sankyo; Pfizer
 
Jun Amaki
No Relationships to Disclose
 
Toshinori Soejima
No Relationships to Disclose
 
Bungo Saito
No Relationships to Disclose
 
Emiko Shimoda
No Relationships to Disclose
 
Noriko Fukuhara
Honoraria - Bristol-Myers Squibb Japan; Celgene; Janssen; Ono Pharmaceutical; Takeda; Zenyaku Kogyo
Research Funding - Eisai (Inst)
 
Norifumi Tsukamoto
No Relationships to Disclose
 
Kazuyuki Shimada
Honoraria - Bristol-Myers Squibb Japan; Celgene; Eisai; Kyowa Hakko Kirin
 
Ilseung Choi
No Relationships to Disclose
 
Takahiko Utsumi
No Relationships to Disclose
 
Yasuo Ejima
No Relationships to Disclose
 
Naoyuki Katayama
Honoraria - Alexion Pharmaceuticals; Astellas Pharma; Bristol-Myers Squibb Japan; Celgene; Chugai Pharma; Dainippon Sumitomo Pharma; Janssen; Kyowa Hakko Kirin; Nippon Shinyaku; Novartis; Novo Nordisk; Pfizer; Shionogi; Shire; Taisho Toyama Pharma; Takeda
Research Funding - Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Nippon Shinyaku (Inst); Novartis (Inst); Novo Nordisk (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Shionogi (Inst); Takeda (Inst); Teijin Pharma (Inst); Toyama Chemical Co (Inst)